NEW YORK (GenomeWeb News) – Synthetic Genomics has sold one million shares to the Malaysian company Dragasic, a subsidiary of the Genting Group, for $8 million, Genting said today, according to the Malaysian news agency Bernama.
Genting said that the Class A common stock it purchased from Synthetic Genomics Founder, Chariman, and CEO Craig Venter represents a roughly two percent economic interest and three percent voting interest in the La Jolla, Calif.-based company.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.